2021 Fiscal Year Final Research Report
Elucidation of molecular mechanism of ferroptosis and construction of new therapeutic strategy in renal cell carcinoma
| Project/Area Number |
19K09731
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56030:Urology-related
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
大庭 康司郎 長崎大学, 病院(医学系), 講師 (20593825)
宮田 康好 長崎大学, 医歯薬学総合研究科(医学系), 准教授 (60380888)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 腫瘍学 / 腎細胞癌 / 薬物療法 / 治療効果 |
|---|
| Outline of Final Research Achievements |
It is now clear that iron kinetics, or iron metabolism, in the body plays an important role in the pathogenesis and progression of malignant tumors such as renal cancer. In addition, there are events such as iron-dependent cell death (i.e., ferrotosis), and their role in the pathology and molecular mechanisms of renal cancer is still unclear. In this study, we sought to elucidate the clinicopathological characteristics of ferrotosis-related factors in renal cancer and explored their potential as markers for therapeutic efficacy of molecularly targeted drugs or immune checkpoint inhibitors, which are the major recent drugs for renal cancer. We also elucidated the role of various cytokines as associated factors.
|
| Free Research Field |
泌尿器科学
|
| Academic Significance and Societal Importance of the Research Achievements |
転移性腎癌などの進行腎癌の主たる治療には、分子標的療法あるいは免疫チェックポイント阻害剤を用いた免疫療法がある。近年、治療方法の改善により、進行腎癌の生命予後も以前と比較して改善している。ただし、多くの症例は、予後不良であり、フェロトーシスやフェロトーシス関連因子としてのサイトカインの動態の解明は、治療効果を予測する臨床的マーカーとなる可能性がある。さらに病理学的特徴と臨床的マーカーの関連性を占めることにより、適切な治療選択の可能性の幅が広がると考えられる。
|
